Evolution of the main clinical variables according to success or failure of discontinuation of omalizumab treatment
| Variable | Group | Pretreatment (PT) | Cessation (VC) | Visit 6 months (V6) | PT* | VC* | V6* | PT† vs VC | PT† vs V6 | VC† vs V6 |
| GETE | Success | – | 3.6±0.5 4.0 (3.0–4.0) | 3.1±0.9 3.0 (3.0–4.0) | – | n.s. | 0.0098 | – | – | 0.0002 |
| Failure | – | 3.3±0.8 3.5 (3.0–4.0) | 2.0±1.3 2.0 (1.0–3.0) | – | n.s. | – | – | 0.0313 | ||
| ACT | Success | 15.1±5.5 15.0 (10.0–20.0) | 22.4±2.7 23.0 (21.0–24.0) | 20.3±4.1 21.0 (16.0–24.0) | n.s. | n.s. | 0.0036 | <0.0001 | <0.0001 | 0.0007 |
| Failure | 12.4±5.2 13.0 (10.0–15.0) | 20.4±3.7 21.5 (18.0–23.0) | 14.5±5.9 13.0 (10.0–20.0) | n.s. | n.s. | 0.0029 | n.s. | 0.0234 | ||
| Exacerbation rate | Success | 4.4±3.3 3.0 (2.0–6.0) | 0.0 (0.0–0.0) 0.0 (0.0–0.0) | 0.4±0.8 0.0 (0.0–1.0) | n.s. | n.s. | 0.0030 | <0.0001 | <0.0001 | n.s. |
| Failure | 4.8±3.9 3.5 (1.5–9.5) | 0.0±0.0 0.0 (0.0–0.0) | 1.5±1.1 2.0 (0.0–2.0) | n.s. | n.s. | 0.0010 | 0.0195 | 0.0078 | ||
| FEV1(%) | Success | 63.6±20.3 61.8 (51.7–70.3) | 70.4±15.7 68.6 (59.0–79.4) | 68.1±14.5 64.6 (61.2–72.3) | n.s. | n.s. | n.s. | 0.0276 | 0.0296 | n.s. |
| Failure | 68.3±19.4 70.7 (59.6–81.6) | 76.2±18.3 80.6 (64.2–89.2) | 67.1±22.1 71.7 (40.8–83.4) | n.s. | n.s. | n.s. | n.s. | n.s. | ||
| IgE (UI/mL) | Success | 462.2±894.1 180.0 (78.0–393.0) | 546.8±515.9 346.0 (210.0–632.0) | 398.0±510.6 217.0 (92.0–412.0) | n.s. | n.s. | n.s. | 0.0113 | n.s. | 0.0003 |
| Failure | 322.4±243.7 304.0 (148.0–354.0) | 710.5±354.9 780.0 (372.0–965.0) | 320.6±171.2 309.0 (162.0–494.0) | n.s. | n.s. | 0.0010 | n.s. | 0.0039 | ||
| Absolute serum eosinophils (109/L) | Success | 378.8±361.6 300.0 (100.0–400.0) | 456.2±562.5 300.0 (100.0–600.0) | – | n.s. | n.s. | – | – | n.s. | |
| Failure | 395.5±226.3 400.0 (200.0–600.0) | 585.7±333.8 500.0 (400.0–600.0) | – | n.s. | – | – | 0.0156 |
Each cell shows the mean±SD and the median (p25–p75) of the clinical variable in each group according to success/failure of the suspension, for each study visit.
*p Values of the statistically significant differences observed between the success and failure groups of the suspension for the variable at the indicated visit.
†p Values of the statistically significant differences observed for the variable at the indicated visits, compared in the success or failure group of the suspension.
ACT, Asthma Control Test; GETE, Global Evaluation of Therapeutic Efficacy; n.s., no statistically significant difference; VC, visit of cessation.